{"id":"https://openalex.org/W2928904403","doi":null,"title":"Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.","display_name":"Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.","alternate_titles":[],"publication_year":2017,"publication_date":"2017-07-15","ids":{"openalex":"https://openalex.org/W2928904403","mag":"2928904403","pmid":"https://pubmed.ncbi.nlm.nih.gov/28712098"},"language":"en","primary_location":{"id":"pmid:28712098","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28712098","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2928904403"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055915497","display_name":"Benjamin Adam Weinberg","orcid":"https://orcid.org/0000-0002-0408-4817","observed_orcids":["https://orcid.org/0000-0002-0408-4817"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Benjamin A Weinberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018018065","display_name":"Marion L. Hartley","orcid":"https://orcid.org/0000-0001-5516-297X","observed_orcids":["https://orcid.org/0000-0001-5516-297X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marion L Hartley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5009223406","display_name":"Mohamed E. Salem","orcid":"https://orcid.org/0000-0002-3661-6785","observed_orcids":["https://orcid.org/0000-0002-3661-6785"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mohamed E Salem","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.047,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.76828712,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"31","issue":"7","first_page":"539","last_page":"548"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.8410000205039978},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.8920000195503235},{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":1.0},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/ziv-aflibercept","display_name":"ziv-aflibercept","score":0.8920000195503235},{"id":"https://openalex.org/keywords/regorafenib","display_name":"regorafenib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tumor-sidedness","display_name":"tumor sidedness","score":0.9010000228881836},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.656000018119812},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.7049999833106995},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.8209999799728394},{"id":"https://openalex.org/keywords/precision-medicine","display_name":"precision medicine","score":0.4580000042915344}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8878176212310791},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8335011005401611},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.823753297328949},{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.8139351606369019},{"id":"https://openalex.org/C2776248978","wikidata":"https://www.wikidata.org/wiki/Q3891664","display_name":"Regorafenib","level":4,"score":0.7231858968734741},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.6790631413459778},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6581600904464722},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.6082857251167297},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.602836549282074},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5822194218635559},{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.5578530430793762},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5072033405303955},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.48304063081741333},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.4781975746154785},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4558407962322235},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4243968427181244},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4235464930534363},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38896727561950684},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.29826655983924866},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.07759061455726624},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001691","descriptor_name":"Biological Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D057285","descriptor_name":"Precision Medicine","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:28712098","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28712098","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:2928904403","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28712098","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2953739922","https://openalex.org/W2518932857","https://openalex.org/W2014013659","https://openalex.org/W2935794657","https://openalex.org/W1972994612","https://openalex.org/W76115934","https://openalex.org/W2015634560","https://openalex.org/W1905914595","https://openalex.org/W2566782051"],"abstract_inverted_index":{"The":[0],"survival":[1,16,60],"of":[2,68],"patients":[3,32,117,152],"with":[4,14,33,118,141,153],"metastatic":[5,34,109],"colorectal":[6,35],"cancer":[7],"has":[8],"improved":[9,59],"dramatically":[10],"in":[11,20,62,106],"recent":[12],"years,":[13],"overall":[15],"exceeding":[17],"3":[18],"years":[19],"large":[21],"randomized":[22],"clinical":[23],"trials.":[24],"There":[25],"are":[26],"now":[27],"several":[28],"treatment":[29,112],"options":[30],"for":[31,183],"cancer.":[36],"In":[37],"addition":[38],"to":[39,57,116,180],"chemotherapy":[40],"backbones":[41],"utilizing":[42],"fluoropyrimidine,":[43],"oxaliplatin,":[44],"and":[45,78,80,90,103,121,133,169,178],"irinotecan":[46],"combinations,":[47],"biologic":[48],"agents":[49,182],"that":[50,165],"target":[51,166],"specific":[52],"oncogenic":[53],"pathways":[54],"have":[55],"contributed":[56],"the":[58,94,100,107,167],"observed":[61],"this":[63],"patient":[64,174],"population.":[65],"This":[66],"class":[67],"medications":[69],"includes":[70],"epidermal":[71],"growth":[72,83],"factor":[73,84],"receptor":[74],"(EGFR)-targeted":[75],"drugs":[76,164],"(cetuximab":[77],"panitumumab)":[79],"vascular":[81],"endothelial":[82],"(VEGF)-targeted":[85],"therapies":[86,150],"(bevacizumab,":[87],"ramucirumab,":[88],"ziv-aflibercept,":[89],"regorafenib).":[91],"Bevacizumab":[92],"remains":[93],"only":[95],"VEGF-targeted":[96],"agent":[97],"approved":[98],"by":[99],"US":[101],"Food":[102],"Drug":[104],"Administration":[105],"first-line":[108,184],"setting.":[110],"EGFR-directed":[111],"should":[113],"be":[114,128],"restricted":[115],"extended":[119],"RAS":[120],"BRAF":[122],"wild-type":[123],"tumors.":[124],"Tumor":[125],"sidedness":[126],"may":[127],"a":[129],"more":[130,158],"powerful":[131],"prognostic":[132],"predictive":[134],"biomarker":[135],"than":[136],"tumor":[137],"mutational":[138],"profile.":[139],"Patients":[140],"left-sided":[142],"primary":[143,155],"tumors":[144,156],"derive":[145],"greater":[146],"benefit":[147,157],"from":[148,159],"EGFR-targeted":[149],"whereas":[151],"right-sided":[154],"bevacizumab.":[160],"Herein":[161],"we":[162],"review":[163],"EGFR":[168],"VEGF":[170],"pathways,":[171],"focusing":[172],"on":[173],"selection,":[175],"drug":[176],"toxicities,":[177],"how":[179],"choose":[181],"therapy.":[185]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2928904403","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2019-04-11T00:00:00"}
